Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;15(2):211-223.
doi: 10.1007/s11739-019-02268-0. Epub 2019 Dec 31.

Stigmatisation and resilience in inflammatory bowel disease

Marco Vincenzo Lenti  1 , Sara Cococcia  1 , Jihane Ghorayeb  2 , Antonio Di Sabatino  1 , Christian P Selinger  3
Affiliations
Review

Stigmatisation and resilience in inflammatory bowel disease

Marco Vincenzo Lenti et al. Intern Emerg Med. 2020 Mar.

Abstract

Inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, is an immune-mediated, chronic relapsing disorder characterised by severe gastrointestinal symptoms that dramatically impair patients' quality of life, affecting psychological, physical, sexual, and social functions. As a consequence, patients suffering from this condition may perceive social stigmatisation, which is the identification of negative attributes that distinguish a person as different and worthy of separation from the group. Stigmatisation has been widely studied in different chronic conditions, especially in mental illnesses and HIV-infected patients. There is a growing interest also for patients with inflammatory bowel disease, in which the possibility of disease flare and surgery-related issues seem to be the most important factors determining stigmatisation. Conversely, resilience represents the quality that allows one to adopt a positive attitude and good adjustments despite adverse life events. Likewise, resilience has been studied in different populations, age groups, and chronic conditions, especially mental illnesses and cancer, but little is known about this issue in patients with inflammatory bowel disease, even if this could be an interesting area of research. Resilience can be strengthened through dedicated interventions that could potentially improve the ability to cope with the disease. In this paper, we focus on the current knowledge of stigmatisation and resilience in patients with inflammatory bowel disease.

Keywords: Crohn’s disease; Quality of life; Ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Flow diagram of paper selection that was performed through Pubmed for articles written in English. The main research question regarded the evaluation of stigmatisation and resilience in patients suffering from inflammatory bowel disease. The medical subject heading terms “Crohn’s disease” and “ulcerative colitis” were also used. More general articles dealing with how to define and how to measure stigmatisation and resilience were used to provide background for the purpose of the review
Fig. 2
Fig. 2
Summary of the most relevant features of stigmatisation and resilience and their influencing factors. Low resilience may favour stigmatisation, whilst resistance to stigma may strengthen resilience. Inflammatory bowel disease is burdened by a number of disease-specific issues that favour social stigmatisation and may affect resilience
See this image and copyright information in PMC

References

    1. Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagórowicz E, Raine T, Harbord M, Rieder F, European Crohn’s and Colitis Organisation [ECCO] Third European Evidence-Based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649–670. doi: 10.1093/ecco-jcc/jjx008. - DOI - PubMed
    1. Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P, ECCO 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3–25. doi: 10.1093/ecco-jcc/jjw168. - DOI - PubMed
    1. Di Sabatino A, Rovedatti L, Vidali F, Macdonald TT, Corazza GR. Recent advances in understanding Crohn's disease. Intern Emerg Med. 2013;8:101–113. doi: 10.1007/s11739-011-0599-2. - DOI - PubMed
    1. Di Sabatino A, Biancheri P, Rovedatti L, Macdonald TT, Corazza GR. Recent advances in understanding ulcerative colitis. Intern Emerg Med. 2012;7:103–111. doi: 10.1007/s11739-011-0719-z. - DOI - PubMed
    1. Selinger CP, Andrews JM, Titman A, Norton I, Jones DB, McDonald C, Barr G, Selby W, Leong RW, Sydney IBD Cohort Study Group Collaborators Long-term follow up reveals low incidence of colorectal cancer, but frequent need for resection, among Australian patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;12:644–650. doi: 10.1016/j.cgh.2013.05.017. - DOI - PubMed